Does it really matter? The IP will pay for itself very soon once Lilly finalizes the NR2F6 deal and hands Koos billions of dollars as we have been told it will do once the human patent was announced.
The best part of this update is that it appears the terms of the payments seem to use a share price calculation based on the numbers of shares due based on each month's RGBP share price, not only the March price!! My prior calculations were based on the price in March (and that's all we had at that point). Now that we've taken yet another tumble, it takes even more shares to make the payment! (aka, the death spiral)
The 8K shows that the last payment was based on a share price of 0.0033! The first payment was based on a share price around 0.006! So my estimate of 250 million shares to pay off the entire debt, based on the March price, is too low! The actual number of shares to pay off this "small debt" will be closer to 400 million shares!
We've got 2 payments left, and each of those will be about 100 million shares, unless this POS falls even more! (fingers crossed).
See the other two posts in this thread for the spot on analysis of the debt payments which I posted here MONTHS ago!